BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

822 related articles for article (PubMed ID: 17545610)

  • 1. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
    Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
    Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunologic evaluation of peptides derived from BCR/ABL-out-of-frame fusion protein in HLA A2.1 transgenic mice.
    Casnici C; Volpe G; Crotta K; Lattuada D; Saglio G; Marelli O
    J Immunother; 2012 May; 35(4):321-8. PubMed ID: 22495389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice.
    Casnici C; Volpe G; Lattuada D; Crotta K; Kuka M; Panuzzo C; Mastrotto C; Tonon G; Fazio VM; Saglio G; Marelli O
    Cancer Lett; 2009 Apr; 276(1):61-7. PubMed ID: 19062160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a monoclonal antibody specific for novel Bcr/Abl out-of-frame fusion proteins.
    Casnici C; Volpe G; Crotta K; Panuzzo C; Lattuada D; Cabras CA; Longhi R; Saglio G; Marelli O
    Hybridoma (Larchmt); 2011 Jun; 30(3):261-9. PubMed ID: 21707361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.
    Buzyn A; Ostankovitch M; Zerbib A; Kemula M; Connan F; Varet B; Guillet JG; Choppin J
    Eur J Immunol; 1997 Aug; 27(8):2066-72. PubMed ID: 9295046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.
    Kessler JH; Bres-Vloemans SA; van Veelen PA; de Ru A; Huijbers IJ; Camps M; Mulder A; Offringa R; Drijfhout JW; Leeksma OC; Ossendorp F; Melief CJ
    Leukemia; 2006 Oct; 20(10):1738-50. PubMed ID: 16932347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules.
    Schmitt M; Li L; Giannopoulos K; Chen J; Brunner C; Barth T; Schmitt A; Wiesneth M; Döhner K; Döhner H; Greiner J
    Exp Hematol; 2006 Dec; 34(12):1709-19. PubMed ID: 17157168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.
    Grünebach F; Mirakaj V; Mirakaj V; Müller MR; Brümmendorf T; Brossart P
    Cancer Res; 2006 Jun; 66(11):5892-900. PubMed ID: 16740729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.
    Yotnda P; Firat H; Garcia-Pons F; Garcia Z; Gourru G; Vernant JP; Lemonnier FA; Leblond V; Langlade-Demoyen P
    J Clin Invest; 1998 May; 101(10):2290-6. PubMed ID: 9593785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological characterization of the tumor-specific bcr/abl junction of Philadelphia chromosome positive chronic myeloid leukemia.
    Barrett J; Guimaraes A; Cullis J; Goldman JM
    Stem Cells; 1993 Oct; 11 Suppl 3():104-8. PubMed ID: 8298471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Two Ph chromosome positive chronic myelogenous leukemia patients with rare bcr/abl fusion gene].
    Qin YZ; Liu YR; Li JL; Wang H; Chang Y; Fu JY; Ruan GR; Shi HL; Qiu JY; Lu DP; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):409-12. PubMed ID: 15355693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11).
    Mundhada S; Luthra R; Cano P
    BMC Cancer; 2004 Jun; 4():25. PubMed ID: 15202948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients.
    Bertazzoli C; Marchesi E; Passoni L; Barni R; Ravagnani F; Lombardo C; Corneo GM; Pioltelli P; Pogliani E; Gambacorti-Passerini C
    Clin Cancer Res; 2000 May; 6(5):1931-5. PubMed ID: 10815918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
    Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
    Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection on BCR-ABL fusion gene in Ph1 chromosome positive leukemia by "nested" retrotranscriptase/polymerase chain reaction].
    Huang W; Cao Q; Lu Y
    Zhonghua Yi Xue Za Zhi; 1994 Nov; 74(11):662-5, 708. PubMed ID: 7866899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects.
    Butt NM; Rojas JM; Wang L; Christmas SE; Abu-Eisha HM; Clark RE
    Haematologica; 2005 Oct; 90(10):1315-23. PubMed ID: 16219567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+ chronic myeloid leukaemia.
    Westermann J; Kopp J; van Lessen A; Hecker AC; Baskaynak G; le Coutre P; Döhner K; Döhner H; Dörken B; Pezzutto A
    Br J Haematol; 2007 May; 137(4):297-306. PubMed ID: 17408402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules.
    Berke Z; Andersen MH; Pedersen M; Fugger L; Zeuthen J; Haurum JS
    Leukemia; 2000 Mar; 14(3):419-26. PubMed ID: 10720136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia.
    Guo JQ; Hirsch-Ginsberg CF; Xian YM; Stass SA; Champlin RE; Giralt SA; McCredie KB; Campbell ML; Arlinghaus RB
    Hematol Pathol; 1993; 7(2):91-106. PubMed ID: 8340287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of BCR/ABL fusion proteins on the course of Ph leukemias.
    Telegeev GD; Dubrovska AN; Dybkov MV; Maliuta SS
    Acta Biochim Pol; 2004; 51(3):845-9. PubMed ID: 15448745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.